解读上腺素类似放射性药物的对有机阴离子转运器亲和力的结构影响
Saskia Mühlig1, Xinyu Chen2, Anna Tutov3
1Department of Nuclear Medicine and Comprehensive Heart Failure Center, University Hospital Würzburg, Würzburg, Germany.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|October 31, 2025
概括
针对北上腺素转运体 (NET) 的放射性追踪剂的结构性修改可以减少有机阴离子转运体 (OCT) 的吸收. 这项研究确定了设计更有选择性的NET配体的关键因素,这些配体具有更好的异位潜力.
科学领域:
- 放射性药物化学 放射性药物化学
- 分子成像学分子成像学
- 药理学 药理学是指药理学的学科.
背景情况:
- 对神经和心脏病的成像非常重要.
- 以前的无线电追踪器,如[123I]MIBG,由于与其他传送器的不清楚相互作用,显示出局限性.
- 有机阴离子载体 (OCT) 参与了一些NET向剂的非特异性吸收.
研究的目的:
- 调查NET准无线电追踪器的结构设计如何影响OCT介导的吸收.
- 确定调节对NET和OCT亲和力的化学特征.
- 引导开发更有选择性的NET成像代理.
主要方法:
- 使用表达NET和OCT的细胞进行细胞吸收测定 (OCT1,OCT2,OCT3).
- 与各种NET向放射性药物和新型PET标记剂 ([18F]AF78和类似物) 进行竞争性结合试验.
- 在非人类灵长类动物体内动态PET成像,以评估在NET抑制后的[18F]AF78吸收.
主要成果:
- 基于单胺的标记剂显示出高的NET选择性,而含瓜尼丁的标记剂具有显著的OCT亲和力.
- 瓜尼丁化合物中较低的脂性与减少的OCT相互作用相关.
- PET成像证实[18F]AF78心脏吸收是NET特异性的,但肝脏保留表明OCT参与.
结论:
- 复合结构对NET和OCT的亲属关系产生了重大影响.
- 减少OCT吸收的修改,同时保持NET亲和力,可以提高放射性追踪器的特异性.
- 这些发现有助于设计下一代NET向配体,以提高临床效用.
更多相关视频
相关概念视频
Drugs Affecting Neurotransmitter Release or Uptake
1.5K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.5K
Adrenergic Agonists: Indirect-Acting Agents
2.6K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.6K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.8K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.8K
Drugs Affecting Neurotransmitter Synthesis
2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K
Adrenergic Agonists: Direct-Acting Agents
2.6K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
2.6K
Drug-Receptor Interactions
7.3K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
7.3K
![Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [11C]SNAP-7941](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F59557.jpg&w=3840&q=50)

